Objective:
To discuss the evolution of Age-Related Eye Disease Study (AREDS) formulations and explore potential next-generation AMD supplementation strategies, highlighting the significance of AMD as a leading cause of vision loss.
Key Findings:
- AREDS demonstrated a 25% reduction in progression to advanced AMD in high-risk patients, establishing supplementation as a standard care component.
- AREDS2 confirmed the protective effect of lutein and zeaxanthin while eliminating lung cancer risk in smokers, emphasizing safety.
- Omega-3 fatty acids did not reduce progression to advanced AMD in AREDS2, raising questions about their role in supplementation.
- Current formulations do not address key pathways like chronic inflammation and mitochondrial dysfunction, indicating a need for further research.
Interpretation:
Future AMD supplementation strategies may need to be personalized, considering genetic, dietary, and health factors to address a broader range of biological mechanisms beyond oxidative stress.
Limitations:
- AREDS2 does not target chronic inflammation and complement dysregulation, which are key drivers of disease progression.
- Mitochondrial dysfunction is not addressed in current formulations, highlighting a gap in treatment.
- The one-size-fits-all model may not reflect the heterogeneity of AMD, suggesting a need for personalized approaches.
Conclusion:
The National Eye Institute is developing an AREDS3 study to evaluate additional supplemental strategies for AMD, particularly for patients with geographic atrophy, underscoring the importance of ongoing research.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.